ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,954.50
1.59%
US Tech 100
20,332.80
1.61%
Dow Jones
43,840.91
1.39%
Brent Oil
73.045
0.00%
Bitcoin
85,872.41
-0.19%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. 4D Molecular Therapeutics Inc (FDMT) Quote

4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc (FDMT)

NASDAQ
4.53
0.05
(1.12%)
Closed March 02 4:00PM
Delayed by 15 minutes
4.63
0.10
(2.21%)
After Hours: 7:45PM
Delayed by 15 minutes
Advanced chart

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
4.63
Bid
2.71
Ask
15.00
Volume
1,233,487
4.20 Day's Range 4.64
4.405 52 Week Range 36.25
Market Cap
214.034M
Previous Close
4.48
Open
4.45
Last Trade
100
@
4.63
(formt)
Last Trade Time
Financial Volume
$ 5,479,234
VWAP
4.4421
Average Volume (3m)
921,463
Shares Outstanding
46,227,709
Dividend Yield
-
PE Ratio
-2.09
Earnings Per Share (EPS)
-2.18
Revenue
20.72M
Net Profit
-100.84M

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.4dmoleculartherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
4D Molecular Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker FDMT. The last closing price for 4D Molecular Therapeutics was $4.48. Over the last year, 4D Molecular Therapeutics shares have traded in a share price range of $ 4.405 to $ 36.25.

4D Molecular Therapeutics currently has 46,227,709 shares outstanding. The market capitalization of 4D Molecular Therapeutics is $207.10 million. 4D Molecular Therapeutics has a price to earnings ratio (PE ratio) of -2.09.

Ask ADVFN Intelligence (AI)

FDMT Latest News

More News

Form POS AM - Post-Effective amendments for registration statement
Edgar (US Regulatory)
February 28 2025
FDMT (1.12%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
February 28 2025
FDMT (1.12%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 28 2025
FDMT (1.12%)

Form 8-K - Current report
Edgar (US Regulatory)
February 28 2025
FDMT (1.12%)

Form 8-K - Current report
Edgar (US Regulatory)
February 10 2025
FDMT (1.12%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.11-2.320675105494.744.8654.445071504.60495001CS
4-0.99-17.6156583635.626.914.4059560905.3269512CS
12-2.2585-32.78652827186.88857.584.4059214635.62667812CS
26-10.87-70.129032258115.517.314.4058807658.11781786CS
52-25.02-84.384485666129.6536.254.40580888314.88750404CS
156-9.76-67.824878387814.3936.254.40557373316.83174549CS
260-35.37-88.4254055.114.40546546618.33281689CS

FDMT - Frequently Asked Questions (FAQ)

What is the current 4D Molecular Therapeutics share price?
The current share price of 4D Molecular Therapeutics is $ 4.63
How many 4D Molecular Therapeutics shares are in issue?
4D Molecular Therapeutics has 46,227,709 shares in issue
What is the market cap of 4D Molecular Therapeutics?
The market capitalisation of 4D Molecular Therapeutics is USD 207.1M
What is the 1 year trading range for 4D Molecular Therapeutics share price?
4D Molecular Therapeutics has traded in the range of $ 4.405 to $ 36.25 during the past year
What is the PE ratio of 4D Molecular Therapeutics?
The price to earnings ratio of 4D Molecular Therapeutics is -2.09
What is the cash to sales ratio of 4D Molecular Therapeutics?
The cash to sales ratio of 4D Molecular Therapeutics is 10.15
What is the reporting currency for 4D Molecular Therapeutics?
4D Molecular Therapeutics reports financial results in USD
What is the latest annual turnover for 4D Molecular Therapeutics?
The latest annual turnover of 4D Molecular Therapeutics is USD 20.72M
What is the latest annual profit for 4D Molecular Therapeutics?
The latest annual profit of 4D Molecular Therapeutics is USD -100.84M
What is the registered address of 4D Molecular Therapeutics?
The registered address for 4D Molecular Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the 4D Molecular Therapeutics website address?
The website address for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com
Which industry sector does 4D Molecular Therapeutics operate in?
4D Molecular Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAKSTAK Inc
$ 3.97
(156.13%)
173.35k
ORGOOrganogenesis Holdings Inc
$ 6.21
(102.28%)
58.69M
TRNRInteractive Strength Inc
$ 2.57
(67.97%)
192.48M
PMAXPowell Max Ltd
$ 0.511
(43.54%)
136.35M
ARBBARB IOT Group Ltd
$ 0.6635
(38.23%)
58.86M
NVNINVNI Group Ltd
$ 0.99
(-50.50%)
72.28M
SPGCSacks Parente Golf Inc
$ 0.2085
(-48.65%)
57.4M
ADGMAdagio Medical Holdings Inc
$ 0.8081
(-47.53%)
756.64k
PRAXPraxis Precision Medicines Inc
$ 38.60
(-40.64%)
3.17M
SAGSAG Holdings Ltd
$ 1.19
(-38.97%)
788.89k
NVDANVIDIA Corporation
$ 124.92
(3.97%)
389.48M
TRNRInteractive Strength Inc
$ 2.57
(67.97%)
193.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 13.44
(7.78%)
154.46M
PMAXPowell Max Ltd
$ 0.511
(43.54%)
137.18M
LCIDLucid Group Inc
$ 2.22
(-0.45%)
136.17M

FDMT Financials

Financials

FDMT Discussion

View Posts
Monksdream Monksdream 2 months ago
FDMT, under $7
👍️0
Monksdream Monksdream 4 months ago
FDMT under $10
👍️0
Monksdream Monksdream 4 months ago
FDMT under $10
👍️0
Biggeoff Biggeoff 1 year ago
$70 price target by $BMO
👍️0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
FDMT
4D Molecular Therapeutics
BOV
ENGI11R
ENERGISA
NASDAQ
LNSR
LENSAR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads